12 results about "Non enveloped virus" patented technology

A pre-saturated wipe product is disclosed that is well suited for destroying non-enveloped viruses, including norovirus. The wipe composition includes a first antimicrobial agent blended with a second agent, such as a preservative. The wipe product can destroy and kill non-enveloped viruses completely in a relatively short contact time, even at very low concentrations in the wipe composition.

The present invention provides a disinfectant composition that is excellent in suppressing skin irritation and has a good effect in inactivating non-enveloped viruses, an article impregnated with the disinfectant composition, a method for inactivating non-enveloped viruses, and a method for producing the disinfectant composition. [Solution] A disinfectant composition containing (A) 40% to 95% by mass of ethanol, (B) 0.20% to 3.0% by mass of one or more selected from gluconic acid and its alkali metal salts, and (C) 0.10% to 2.0% by mass of a water-soluble polyhydric alcohol, with a pH of 5.0 or less at 25°C.

The present invention provides a method of inactivating enveloped viruses during the production of a biologic product without harming the biologic product. The method comprises contacting cells containing the biologic product with at least one purified non-ionic detergent, wherein the detergent(s) lyses the cells to release the biologic product, thereby producing a lysate, and wherein the detergent(s) inactivates any enveloped viruses within the lysate. The detergent can be an ethoxylated alcohol, sorbiton ethoxylate, triblock copolymer and combinations thereof. Examples of biologic products include non-enveloped viruses and therapeutic recombinant proteins produced via lysis of mammalian or insect cells.

The present invention relates to the fields of medicine, gene therapy and medicine, in particular to pharmaceutical compositions of vectors based on recombinant non-enveloped viruses, in particular recombinant adeno-associated viruses (rAVVs), which can be used to treat and prevent various diseases.

A composite quaternary ammonium salt disinfectant includes a double long-chain quaternary ammonium salt, two single long-chain quaternary ammonium salts, a synergist isothiazolinone, a nonionic surfactant fatty alcohol polyvinyl ether, and water, wherein the double long-chain quaternary ammonium salt is dialkyl dimethyl ammonium chloride with dialkyl being two independent alkyl groups with a chain length of C8-C18, and the two single-chain quaternary ammonium salts are alkyl dimethyl benzyl ammonium chloride with an alkyl chain length of C8-C18 and alkyl dimethyl ethyl benzyl ammonium chloride with an alkyl chain length of C8-C18, respectively. The composite quaternary ammonium salt disinfectant has a synergistic effect among its components, which greatly improves the capacity of resisting interferences by hard water and organics; and can kill not only bacterial propagules, lipophilic viruses (enveloped viruses, such as novel coronavirus) and fungi, but also hydrophilic viruses (non-enveloped viruses).

Disclosed are a method and system for thermal stabilization of pharmaceutical formulations containing enveloped and nonenveloped viruses. The disclosed method of Rapid Room Temperature Aerosol Dehydration (RTAD) provides a scalable system for continuous dehydration of liquid pharmaceutical and biopharmaceutical formulations that provides thermal stabilization of biological drugs by converting liquid drugs into powder form, enabling their transportation, storage and handling at room temperature. The disclosed process can generate sprays / aerosols with droplets that are 100x smaller (0.2-20 μm) than existing spray drying technologies and perform dehydration, without applying heat, which mitigates the risk of damage of thermolabile biologicals and provides a significant reduction in energy requirements. The technology has demonstrated superiority of the system over traditional spray drying and freeze drying with respect to energy consumption, biological activity, scalability, powder solubility, particle size and size uniformity, and high-quality of produced inhalable and reconstitutable biologic formulations.

Provided are: a disinfectant composition having an excellent effect of suppressing hand roughness and having a good effect of inactivating a non-enveloped virus; a disinfectant composition-impregnated article; a non-enveloped virus inactivation method; and a method for producing a disinfectant composition.　A disinfectant composition, according to the present invention, contains: (A) 40-95 mass% of ethanol; (B) 0.20-3.0 mass% of one or more substances selected from gluconic acid and alkali metal salts thereof; and (C) 0.10-2.0 mass% of a water-soluble polyhydric alcohol, and has a pH of 5.0 or less at 25°C.

Provided is an antiviral composition that has a photocatalytic function, and exhibits high antiviral activities against non-enveloped viruses that have been so far difficult to inactivate using a silver compound in a dark place not exposed to the light. This antiviral composition contains two types of particles that are photocatalyst particles and silver nanoparticles having a protection agent adsorbed on the surfaces thereof and having a dispersed particle diameter of 1000 nm or less and a primary particle diameter of 500 nm or less. The antiviral activity value, based on JIS R1756:2020, of the composition in a dark place is greater than 0.3, and the antiviral activity value of the composition brought by irradiation with light based on JIS R1756:2020 is at least 0.3.

The present invention relates to the field of pharmaceuticals, gene therapy and medicine, specifically to pharmaceutical compositions of a vector based on recombinant non-enveloped virus, in particular recombinant adeno-associated virus (rAAV), which compositions may be used for the treatment and prophylaxis of various diseases.

A method for flow cytometry evaluation of unassociated non-enveloped viral particles having a non-enveloped viral capsid includes preparing a fluorescently-stained fluid sample in which at least one fluorescent staining step is performed at an acidic pH in an acidic pH range and then subjecting the fluorescently-stained fluid sample to flow cytometry evaluation. A kit includes a plurality of sealed container with a first sealed container containing a fluorescent stain composition and a second sealed container including an aqueous dilution liquid at an acidic pH.

The present invention provides an antiviral decorative sheet which maintains the surface properties of a surface protective layer and which is capable of exerting an antiviral effect even on nonenveloped viruses. Specifically, the antiviral decorative sheet of the present invention has a crosslinking and curing type resin layer in the outermost surface layer, and is characterized in that: (1) the crosslinking and curing type resin layer contains a cured product of a crosslinking and curing type resin and an antiviral agent; and (2) the antiviral agent has antiviral properties against nonenveloped viruses, and contains a carboxylic acid derivative and a styrene polymer derivative, and contains all of triethylamine, N,N-dimethylallylamine, dimethylpyrrole, tetramethyl-1,3-propanediamine and N,N,2,2-tetramethyl-1,3-propanediamine as constituent components of the carboxylic acid derivative.